Another major finding in the present study was the association of high levels of many effector cell populations, such as CD3+, CD4+, and CD8+ T cells or CD19+ B cells, in the HSCT grafts with the more severe aGVHD in AML patients. The gene discussed is CD19; the disease is acute myeloid leukemia.